Merck's Keytruda Shows Recurrence-free Survival In Resected High-Risk Stage II Melanoma

Merck & Co., Inc. (MRK) said that the first results from the Phase 3 KEYNOTE-716 trial, in which adjuvant treatment with the company's anti-PD-1 therapy Keytruda, showed a statistically significant and clinically meaningful improvement in recurrence-free survival (RFS), the trial's primary endpoint, compared to placebo in patients with resected high-risk stage II melanoma.

At the first interim analysis, Keytruda reduced the risk of disease recurrence or death by 35% compared to placebo. Median RFS had not been reached for either group at the time of this analysis. After 14.4 months follow-up, 11.1% of patients on Keytruda had recurrence or died compared with 16.8% of patients on placebo, with fewer distant recurrences with Keytruda versus placebo.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Facebook is planning to create 10,000 new high-skilled jobs within the European Union over the next five years to help build the metaverse, a new concept of a digital world. Metaverse is described as a new phase of interconnected virtual experiences using technologies like virtual and augmented reality. In a blog post, the company stated that the metaverse has the potential to help unlock access.. Walmart is bringing back its month-long savings event "Black Friday Deals for Days" in November, with special early access for Walmart+ members. The retail behemoth, which reinvented the Black Friday shopping events last year, will spread out its Black Friday savings to three events throughout November. Each savings event will begin online at Walmart.com and continue with the same deals in stores. Shares of Philips Electronics NV were losing around 2 percent in the morning trading in Amsterdam after the Dutch consumer electronics giant on Monday trimmed its outlook for fiscal 2021 after reporting weak EBITA and sales in its third quarter. The results were hurt by supply chain challenges as well as Sleep & Respiratory Care recall. However, quarterly net profit was significantly higher.
Follow RTT